HCV Core Protein antibody (AbBy Fluor® 488)

Catalog No. ABIN900295

This Rabbit Polyclonal antibody specifically detects HCV Core Protein in WB. It exhibits reactivity toward Hepatitis C Virus (HCV).

Quick Overview for HCV Core Protein antibody (AbBy Fluor® 488) (ABIN900295)

Target: HCV Core Protein (HCV C) (Hepatitis C Virus Core Protein (HCV C))

Reactivity: Hepatitis C Virus (HCV)

Host: Rabbit

Clonality: Polyclonal

Conjugate: This HCV Core Protein antibody is conjugated to AbBy Fluor® 488

Application: Western Blotting (WB)

Product Details anti-HCV Core Protein Antibody (AbBy Fluor® 488)

Cross-Reactivity: Human, Virus

Cross-Reactivity (Details): HCV

Purification: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from HCV-Core

Isotype: IgG

Application Details

Application Notes: IF(IHC-P) 1:50-200

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Expiry Date: 12 months

Target Details for HCV Core Protein

Target: HCV Core Protein (HCV C) (Hepatitis C Virus Core Protein (HCV C))

Alternative Name: HCV Core Protein

Target Type: Viral Protein

Background:

Synonyms: Core protein p19, Hepatitis C Virus Core Antigen-C, HCVAg, HCV-Core protein,HCV core antigen, HCV core protein, Hepatitis C Virus core protein, capsid protein, polyprotein precursor, Core protein p21, Core protein p9.

Background: Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Plays an important role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Mediates apoptotic pathways throught association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptors-induced apoptosis remains controvertial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Secreted core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. May alter lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage.

UniProt: P26664